

# A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

NCT06524544

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	National Cancer Institute (NCI)
<b>Enrollment</b>	320 participants

## Key Eligibility Criteria

---

### Inclusion (41)

- Patient must be ≥ 18 years of age
- Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Patient must have locally advanced (unresectable or not amenable to curative intent therapy) or metastatic urothelial cancer
- Patient must have histologically proven conventional urothelial carcinoma (UC) of any urinary tract origin \[any histologic subtype except neuroendocrine (small or large cell)\] are permitted so long as tumors include ≥ 1% urothelial histology). NOTE: Pure non-urothelial histology is excluded
- Patient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Baseline imaging must be obtained ≤ 35 days prior to randomization

... and 36 more (see full listing online)

## Locations (106 total)

---

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

UF Health Cancer Institute - Gainesville, Gainesville, Florida, United States

... and 103 more locations